104 related articles for article (PubMed ID: 33796405)
1. Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma.
Arends R; Guo X; Baverel PG; González-García I; Xie J; Morsli N; Yovine A; Roskos LK
Oncoimmunology; 2021 Mar; 10(1):1898104. PubMed ID: 33796405
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Seiwert TY; Wildsmith S; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Baker V; Evans B; Morsli N; Jill Walker ; Real K; L'Hernault A; Psyrri A
Cancer Immunol Immunother; 2024 Mar; 73(4):70. PubMed ID: 38430375
[TBL] [Abstract][Full Text] [Related]
3. Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
Kim DH; Lim ST; Kim HR; Kang EJ; Ahn HK; Lee YG; Sun S; Kwon JH; Lee SC; Lee HW; Kim MK; Keam B; Park KU; Shin SH; Yun HJ
Oral Oncol; 2024 Apr; 151():106739. PubMed ID: 38458039
[TBL] [Abstract][Full Text] [Related]
4. Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.
Moutafi M; Koliou GA; Papaxoinis G; Economopoulou P; Kotsantis I; Gkotzamanidou M; Anastasiou M; Pectasides D; Kyrodimos E; Delides A; Giotakis E; Papadimitriou NG; Panayiotides IG; Perisanidis C; Fernandez AI; Xirou V; Poulios C; Gagari E; Yaghoobi V; Gavrielatou N; Shafi S; Aung TN; Kougioumtzopoulou A; Kouloulias V; Palialexis K; Gkolfinopoulos S; Strati A; Lianidou E; Fountzilas G; Rimm DL; Foukas PG; Psyrri A
Cancer Res Commun; 2023 Aug; 3(8):1514-1523. PubMed ID: 37575280
[TBL] [Abstract][Full Text] [Related]
5. Circulating low density neutrophils are associated with resistance to anti-PD1 immunotherapy in squamous head and neck cancer.
Arrazubi V; Goñi S; González-Borja I; Hernandez-Garcia I; Arasanz H; Pérez-Sanz J; Bocanegra AI; Kochan G; Escors D; Ruiz de Azúa Y; Elizalde JM; Viúdez A; Vera R
Head Neck; 2023 Dec; 45(12):3075-3085. PubMed ID: 37792371
[TBL] [Abstract][Full Text] [Related]
6. Author Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC.
Darragh LB; Knitz MM; Hu J; Clambey ET; Backus J; Dumit A; Samedi V; Bubak A; Greene C; Waxweiler T; Mehrotra S; Bhatia S; Gadwa J; Bickett T; Piper M; Fakhoury K; Liu A; Petit J; Bowles D; Thaker A; Atiyeh K; Goddard J; Hoyer R; Van Bokhoven A; Jordan K; Jimeno A; D'Alessandro A; Raben D; McDermott JD; Karam SD
Nat Cancer; 2023 Jan; 4(1):148. PubMed ID: 36577897
[No Abstract] [Full Text] [Related]
7. Publisher Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC.
Darragh LB; Knitz MM; Hu J; Clambey ET; Backus J; Dumit A; Samedi V; Bubak A; Greene C; Waxweiler T; Mehrotra S; Bhatia S; Gadwa J; Bickett T; Piper M; Fakhoury K; Liu A; Petit J; Bowles D; Thaker A; Atiyeh K; Goddard J; Hoyer R; Van Bokhoven A; Jordan K; Jimeno A; D'Alessandro A; Raben D; McDermott JD; Karam SD
Nat Cancer; 2024 Jan; 5(1):210. PubMed ID: 38200246
[No Abstract] [Full Text] [Related]
8. PD-L1 expression in recurrent head and neck squamous cell carcinoma.
Delafoy A; Uguen A; Lemasson G; Conan-Charlet V; Pradier O; Lucia F; Schick U
Eur Arch Otorhinolaryngol; 2022 Jan; 279(1):343-351. PubMed ID: 33796940
[TBL] [Abstract][Full Text] [Related]
9. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
Powles T; Carroll D; Chowdhury S; Gravis G; Joly F; Carles J; Fléchon A; Maroto P; Petrylak D; Rolland F; Cook N; Balar AV; Sridhar SS; Galsky MD; Grivas P; Ravaud A; Jones R; Cosaert J; Hodgson D; Kozarewa I; Mather R; McEwen R; Mercier F; Landers D
Nat Med; 2021 May; 27(5):793-801. PubMed ID: 33941921
[TBL] [Abstract][Full Text] [Related]
10. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases.
Kanikarla Marie P; Haymaker C; Parra ER; Kim YU; Lazcano R; Gite S; Lorenzini D; Wistuba II; Tidwell RSS; Song X; Foo WC; Maru DM; Chun YS; Futreal A; Kee B; Menter D; Solis L; Tzeng CW; Parseghian C; Raghav K; Morris V; Chang CC; Jenq R; Tam A; Bernatchez C; Kopetz S; Vauthey JN; Overman MJ
Clin Cancer Res; 2021 Jun; 27(11):3039-3049. PubMed ID: 33811152
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting.
Taugner J; Käsmann L; Eze C; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33807324
[TBL] [Abstract][Full Text] [Related]
12. Curative-Intent Treatment with Durvalumab in Early-Stage Cancers.
Melillo G; Chand V; Yovine A; Gupta A; Massacesi C
Adv Ther; 2021 Jun; 38(6):2759-2778. PubMed ID: 33881745
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
[TBL] [Abstract][Full Text] [Related]
14. Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma.
Shibata Y; Kishida T; Kouro T; Wei F; Igarashi Y; Himuro H; Noguchi T; Koizumi M; Suzuki T; Osaka K; Saigusa Y; Sasada T
Front Pharmacol; 2023; 14():1269935. PubMed ID: 38026978
[No Abstract] [Full Text] [Related]
15. Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment.
Merlano MC; Paccagnella M; Denaro N; Abbona A; Galizia D; Sangiolo D; Gammaitoni L; Fiorino E; Minei S; Bossi P; Licitra L; Garrone O
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958430
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis.
Zou D; Song A; Yong W
Front Oncol; 2023; 13():1176574. PubMed ID: 37621675
[TBL] [Abstract][Full Text] [Related]
17. Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures.
Wei F; Azuma K; Nakahara Y; Saito H; Matsuo N; Tagami T; Kouro T; Igarashi Y; Tokito T; Kato T; Kondo T; Murakami S; Usui R; Himuro H; Horaguchi S; Tsuji K; Murotani K; Ban T; Tamura T; Miyagi Y; Sasada T
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37433717
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review.
Tamimi A; Tamimi A; Sorkheh F; Asl SM; Ghafari A; Karimi AG; Erabi G; Pourmontaseri H; Deravi N
Cancer Rep (Hoboken); 2023 May; 6(5):e1802. PubMed ID: 37042307
[TBL] [Abstract][Full Text] [Related]
19. Nine-gene signature and nomogram for predicting survival in patients with head and neck squamous cell carcinoma.
Yang F; Zhou LQ; Yang HW; Wang YJ
Front Genet; 2022; 13():927614. PubMed ID: 36092911
[No Abstract] [Full Text] [Related]
20. Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Mao XC; Yang CC; Yang YF; Yan LJ; Ding ZN; Liu H; Yan YC; Dong ZR; Wang DX; Li T
Front Immunol; 2022; 13():884592. PubMed ID: 36072577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
